S-{1-[5-(6-氨基-9H-嘌呤-9-基)-4-羟基-3-(膦酰氧基)四氢-2-呋喃基]-3,5,9-三羟基-8,8-二甲基-3,5-二氧代-10,14-二氧代-2,4,6-三氧杂-11,15-二氮杂-3lambda5,5lambda5-二磷杂十七烷-17-基}(9E)-9-十六碳烯硫代酸 | 18198-76-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: S-{1-[5-(6-氨基-9H-嘌呤-9-基)-4-羟基-3-(膦酰氧基)四氢-2-呋喃基]-3,5,9-三羟基-8,8-二甲基-3,5-二氧代-10,14-二氧代-2,4,6-三氧杂-11,15-二氮杂-3lambda5,5lambda5-二磷杂十七烷-17-基}(9E)-9-十六碳烯硫代酸
• 中文别名: 盐棕榈油酰辅酶A锂
• 英文名称: palmitoleoyl-CoA
• 英文别名: Palmitoleoyl-Coenzyme A；S-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] (Z)-hexadec-9-enethioate
• CAS: 18198-76-0
• 化学式: C₃₇H₆₄N₇O₁₇P₃S
• 分子量: 1003.94
• InChiKey: QBYOCCWNZAOZTL-MDMKAECGSA-N

物化性质

• 密度：
  1.54±0.1 g/cm3(Predicted)
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  65
• 可旋转键数：
  33
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  389
• 氢给体数：
  9
• 氢受体数：
  22

安全信息

• WGK Germany：
  3
• 储存条件：
  20°C

制备方法与用途

棕榈酰辅酶A锂盐是一种用于生命科学相关研究的生物化学试剂，可以作为生物材料或有机化合物使用。

反应信息

• 作为反应物：
  描述：

  S-{1-[5-(6-氨基-9H-嘌呤-9-基)-4-羟基-3-(膦酰氧基)四氢-2-呋喃基]-3,5,9-三羟基-8,8-二甲基-3,5-二氧代-10,14-二氧代-2,4,6-三氧杂-11,15-二氮杂-3lambda5,5lambda5-二磷杂十七烷-17-基}(9E)-9-十六碳烯硫代酸 、 [14C(U)]-snglycerol-3-phosphate 在 乙二胺四乙酸 、 DL-dithiothreitol 、 bovie serum albumin 、 Erysimum asperum sn-glycerol-3-phosphate acyltransferase 作用下， 以 aq. buffer 为溶剂， 反应 0.17h， 生成
  参考文献：
  名称：

  Possible allostery and oligomerization of recombinant plastidial sn-glycerol-3-phosphate acyltransferase

  摘要：

  Plastidial acyl-acyl carrier protein:sn-glycerol-3-phosphate acyltransferase (GPAT; EC 2.3.1.15) catalyzes the acyl-acyl carrier protein-dependent sn-1 acylation of sn-glycerol 3-phosphate (G3P) to produce lysophosphatic acid. Functional recombinant Erysimum asperum GPAT (EaGPAT), devoid of transit peptide, was produced in yeast. Analysis of the dependence of EaGPAT activity on increasing G3P concentration resulted in a hyperbolic response. EaGPAT exhibited a preference for 18-carbon unsaturated acyl-CoAs. Assays with concentrations of oleoyl-CoA up to 90μM revealed an exponential response to increasing concentrations of acyl donor, and the introduction of increasing concentrations of unlabeled linoleoyl-CoA into the standard reaction mixture resulted in increased incorporation of radiolabeled oleoyl moieties into lysophosphatidic acid. Collectively, the kinetic results suggest that acyl-CoA may act as both substrate and allosteric effector. EaGPAT was also shown to oligomerize to form higher molecular mass multimers, with the monomer and trimer being the predominant forms of the enzyme. Since most allosteric enzyme exhibit quaternary structure, the self-associating properties of EaGPAT are consistent with those of an allosteric enzyme. These results could have important regulatory implications when plastidial GPAT is introduced into a cytoplasmic environment where acyl-CoA is the acyl donor supporting cytoplasmic glycerolipid assembly.

  DOI：

  10.1016/j.abb.2014.05.007

文献信息

• COMPOUNDS AND USES THEREOF
  申请人：Yumanity Therapeutics, Inc.

  公开号：US20190330198A1

  公开（公告）日：2019-10-31

  The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

  本发明涉及用于治疗神经系统疾病的化合物。本发明的化合物可以单独或与其他药用活性剂结合使用，用于治疗或预防神经系统疾病。
• [EN] HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS<br/>[FR] DERIVES HETEROCYCLIQUES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA STEAROYL-COA DESATURASE
  申请人：XENON PHARMACEUTICALS INC

  公开号：WO2006034441A1

  公开（公告）日：2006-03-30

  Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I) where x, y, J, K, W, V, R3, R4, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

  本发明公开了治疗哺乳动物，尤其是人类患有SCD介导的疾病或症状的方法，其中所述方法包括向需要的哺乳动物施用式(I)的化合物，其中在此处定义了x、y、J、K、W、V、R3、R4、R5、R5a、R6、R6a、R7、R7a、R8和R8a。还公开了包含式(I)化合物的药物组合物。
• [EN] COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS ET LEURS UTILISATIONS
  申请人：YUMANITY THERAPEUTICS INC

  公开号：WO2020198026A1

  公开（公告）日：2020-10-01

  The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.

  本发明涉及对神经系统疾病和原发性脑癌治疗中有用的化合物。本发明的化合物，单独或与其他药用活性剂结合使用，可用于治疗或预防神经系统疾病和原发性脑癌。
• HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE
  申请人：Isabel Elise

  公开号：US20110301143A1

  公开（公告）日：2011-12-08

  Heterocyclic compounds of structural formula (I), or a pharmaceutically acceptable salt thereof, wherein W is a R 1 — substituted heteroaryl, R 1 is an heteroaryl ring substituted with an ester or carboxylic acid containing radical, X-T is N—CR 5 R 6 , C═CR 5 or CR 13 —CR 5 R 6 , Y is a bond or —C(O)—, a and b represent an integer selected from 1 to 4, and Ar is an optionally substituted phenyl or naphtyl, are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD) The heterocyclic compounds are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, atherosclerosis, obesity, diabetes, neurological disease, Metabolic Syndrome, insulin resistance, cancer, liver steatosis, and non-alcoholic steatohepatitis.

  结构式（I）的杂环化合物，或其药学上可接受的盐，其中W是R1-取代的杂芳基，R1是取代有酯基或羧基的杂芳基环，X-T是N—CR5R6，C═CR5或CR13—CR5R6，Y是键或—C(O)—，a和b代表选自1到4的整数，Ar是可选择取代的苯基或萘基，是硬脂酰辅酶A 9-脱饱和酶（SCD）的抑制剂。这些杂环化合物对于预防和治疗与异常脂质合成和代谢有关的疾病非常有用，包括心血管疾病、动脉粥样硬化、肥胖症、糖尿病、神经系统疾病、代谢综合征、胰岛素抵抗、癌症、肝脂肪变性和非酒精性脂肪肝。
• [EN] SUBSTITUTE 1, 6-NAPHTHYRIDINES FOR USE AS SCD INHIBITORS<br/>[FR] 1,6-NAPHTYRIDINES SUBSTITUÉES EN VUE D'UNE UTILISATION EN TANT QU'INHIBITEURS DE SCD
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009056556A1

  公开（公告）日：2009-05-07

  The present invention relates to substituted tetrahydronaphthyridine (THN) compounds of the formula (I) and salts thereof, to pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to compounds for inhibiting SCD activity.

  本发明涉及公式（I）的取代四氢萘啶（THN）化合物及其盐，含有它们的药物组合物以及它们在医学上的用途。具体而言，该发明涉及用于抑制SCD活性的化合物。